Investor Relations
Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion
Ad hoc announcement pursuant to Art. 53 LR-Joincare Announcement on Appointment of Vice President of The Company
Time：2024-10-24
Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2024 Fifth Extraordinary General Meeting
Time：2024-10-24
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Leuprorelin Acetate Microspheres for Injection Passing Consistency Evaluation
Time：2024-10-15
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Approval for the New Indication of Tri-torelin Acetate Microspheres for Injection
Time：2024-10-08
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Change of Board Secretary of the Company
Time：2024-09-27
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2024 Fourth Extraordinary General Meeting
Time：2024-09-23
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement On the Additional Ad Hoc Proposal for the Fourth Extraordinary General Meeting in 2024
Time：2024-09-10
Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2024 Fourth Extraordinary General Meeting
Time：2024-09-02
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Plan for the Repurchase of Shares of the Company by Means of Centralized Bidding Transactions
Time：2024-09-02
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Completion of the Re-Election of the Board of Directors and The Supervisory Committee of the Company
Time：2024-08-27
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.